We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Vitamin D Status Determined in Older Adults

By LabMedica International staff writers
Posted on 25 Jun 2019
Print article
Image: The complete extraction-free, fully automated Liaison XL 1,25 dihydroxyvitamin D radioimmunoassay kit (Photo courtesy of DiaSorin).
Image: The complete extraction-free, fully automated Liaison XL 1,25 dihydroxyvitamin D radioimmunoassay kit (Photo courtesy of DiaSorin).
Vitamin D has a known role in bone health, with growing evidence for beneficial effects on muscle strength and other non-skeletal outcomes. Vitamin D deficiency is often associated with adverse health outcomes in older adults. The circulating 25-hydroxyvitamin D (25(OH)D) status predominately relies on UV exposure.

Several known age-related adverse health outcomes, including bone loss, fracture risk, and falls, are associated with suboptimal serum 25-hydroxyvitamin D (25(OH)D) status (the main circulating and diagnostic metabolite of vitamin D) with further evidence for non-skeletal roles in carcinogenesis, immune function, cardiovascular disease, dementia, and all-cause mortality.

Irish scientists led by those at Trinity College (Dublin, Ireland) investigated vitamin D deficiency in community-dwelling, older adults, residing at latitudes 50⁰–55⁰ north and the study included 6,004 adults, aged over 50 years. Deficiency was categorized by two criteria: Institute of Medicine (IOM) (<30 nmol/L) and Endocrine Society (ES) (<50 nmol/L). Serum 25(OH)D was assessed from a fasting blood sample and concentrations of 25(OH)D were analyzed using the Liaison 25-hydroxyvitamin D immunoassay which yields a lower detection limit of 3.0 nmol/L.

The investigators reported that overall, the prevalence of deficiency (<30 nmol/L and <50 nmol/L) was 23.7% and 55.3%, respectively. For older age categories of ≥60 years and ≥65 years, vitamin D deficiency (<30 nmol/L) and deficiency (<50 nmol/L) were similar at 22.6% and 22.5% and 54.2% and 53.9%, respectively. The highest prevalence of deficiency (by IOM) was noted in women aged 80 years and older (36.8%), with the lowest in men aged between 70–79 years (17.3%). The overall mean 25(OH)D was 48.7 ± 23.5 (range; 9–239 nmol/L). Residing in the south of England was associated with a 22.8% lower risk of deficiency.

Maria O'Sullivan, PhD, an Associate Professor in Nutrition and a senior author of the study, said, “'Our study identified factors associated with vitamin D deficiency, including being aged 80+ years, obesity and sedentary lifestyles; all of which are increasing traits in western populations. Furthermore, this is one of the few studies to highlight the importance of non-white ethnicity in vitamin D deficiency in a large study of ageing. The findings are valuable in developing targeted strategies to eliminate vitamin D deficiency (at 30nmol/L) in older populations.”

The authors concluded that the high prevalence of vitamin D deficiency identified in the cohort highlights the need to raise awareness and have adequate public health strategies for achieving optimum vitamin D concentrations to support successful ageing. Based on their findings, there is a particular need to raise awareness and target those most at risk of vitamin D deficiency. The study was published on June 1, 2019, in the journal Nutrients.

Related Links:
Trinity College

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Aspergillus Test
REALQUALITY Aspergillus
New
Immunoassays and Calibrators
QMS Tacrolimus Immunoassays

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.